News
Sandoz’ Mark McCamish ranked 12th most influential person in antibody...
article.wn.com
... industry influencers of today. Mark McCamish, who leads development of biosimilars at Sandoz, was ranked 12th on the list which includes.
Mark McCamish | EuropaWire.eu
news.europawire.eu
Trial expected to support registration in the U.S. and European Union Sandoz continues to advance biosimilar pipeline with seven Phase III ...
FDA Advisory Committee Recommends Sandoz's Biosimilar Filgrastim for...
www.dcatvci.org
Shows a blog entry in detail
FDA Heads Into Uncharted Territory Of ‘Biosimiliar’ Drugs | Kaiser...
khn.org
Under a new process set out by the health law, the FDA approved the first so-called biosimilar drug for sale in the U.S. It’s a copy of the cancer medicine...
sorted by relevance / date